ITEM 8.01 Other Events.
On February 18, 2009, GTx, Inc. issued a press release announcing that the United States Food and Drug Administration (FDA) has accepted for filing and review the New Drug Application (NDA) for toremifene 80 mg, an oral selective estrogen receptor modulator, which GTx seeks to market for the prevention of bone fractures in men with prostate cancer on androgen deprivation therapy (ADT), a copy of which is furnished as Exhibit 99.1 to this Current Report. This release is furnished by GTx pursuant to Item 2.02 of Form 8-K and is not to be considered "filed" under the Exchange Act, and shall not be incorporated by reference into any previous or future filing by the Registrant under the Securities Act or the Exchange Act.
ITEM 9.01 Financial Statements and Exhibits.

(c) Exhibits Exhibit Number Description 99.1 Press Release issued by GTx, Inc. dated February 18, 2009

---